Ftse Mib
36.137,46
-0,36%
DAX
20.912,48
0,07%
S&P 500
5.996,66
1,00%
NASDAQ
19.630,20
1,51%
Bitcoin
108.450,37
5,18%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Beam Therapeutics Inc (BEAM) Beam Therapeutics Inc (BEAM) Notizie

BEAM

Beam Therapeutics (BEAM)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BEAM
DataOraFonteTitoloSimboloCompagnia
13/01/202513:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
13/01/202513:00GlobeNewswire Inc.Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated CatalystsNASDAQ:BEAMBeam Therapeutics Inc
06/01/202523:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
31/12/202401:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BEAMBeam Therapeutics Inc
19/12/202422:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
17/12/202413:00GlobeNewswire Inc.Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
08/12/202419:45GlobeNewswire Inc.Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual MeetingNASDAQ:BEAMBeam Therapeutics Inc
07/12/202417:30GlobeNewswire Inc.Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual MeetingNASDAQ:BEAMBeam Therapeutics Inc
06/12/202413:00GlobeNewswire Inc.Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial OfficerNASDAQ:BEAMBeam Therapeutics Inc
04/12/202413:00GlobeNewswire Inc.Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial LeaderNASDAQ:BEAMBeam Therapeutics Inc
12/11/202422:01GlobeNewswire Inc.Beam Therapeutics to Participate in 2024 Jefferies London Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
05/11/202415:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BEAMBeam Therapeutics Inc
05/11/202415:00GlobeNewswire Inc.Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual MeetingNASDAQ:BEAMBeam Therapeutics Inc
05/11/202412:30GlobeNewswire Inc.Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority ProgramsNASDAQ:BEAMBeam Therapeutics Inc
29/10/202411:30GlobeNewswire Inc.Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual MeetingNASDAQ:BEAMBeam Therapeutics Inc
21/10/202422:11Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:BEAMBeam Therapeutics Inc
06/08/202412:30GlobeNewswire Inc.Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial ResultsNASDAQ:BEAMBeam Therapeutics Inc
15/07/202412:30GlobeNewswire Inc.Beam Therapeutics Announces Transition of Chief Financial OfficerNASDAQ:BEAMBeam Therapeutics Inc
26/06/202412:30GlobeNewswire Inc.Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)NASDAQ:BEAMBeam Therapeutics Inc
14/06/202409:00GlobeNewswire Inc.Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell DiseaseNASDAQ:BEAMBeam Therapeutics Inc
30/05/202412:30GlobeNewswire Inc.Beam Therapeutics to Participate in Jefferies Global Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
14/05/202422:00GlobeNewswire Inc.Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid CongressNASDAQ:BEAMBeam Therapeutics Inc
08/05/202412:30GlobeNewswire Inc.Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
07/05/202412:30GlobeNewswire Inc.Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial ResultsNASDAQ:BEAMBeam Therapeutics Inc
26/03/202411:30GlobeNewswire Inc.Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)NASDAQ:BEAMBeam Therapeutics Inc
28/02/202412:30GlobeNewswire Inc.Beam Therapeutics to Participate in Upcoming March 2024 Investor ConferencesNASDAQ:BEAMBeam Therapeutics Inc
27/02/202413:40Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BEAMBeam Therapeutics Inc
27/02/202413:22Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BEAMBeam Therapeutics Inc
27/02/202412:30GlobeNewswire Inc.Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated MilestonesNASDAQ:BEAMBeam Therapeutics Inc
05/02/202412:30GlobeNewswire Inc.Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:BEAMBeam Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BEAM

La tua Cronologia

NASDAQ
BEAM
Beam Therapeutics
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network